Status:
UNKNOWN
Impact of Raltegravir on the Viral Reservoirs
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
HIV Infection
Eligibility:
All Genders
18-60 years
Brief Summary
The objective of the antiretroviral treatment is to inhibit the viral replication, estimated(appreciated) by the measure of the viral plasmatic load(responsibility). In this inhibition of the viral re...
Detailed Description
20 patients will be included and followed over a period of 12 months Population of the essay Criteria of inclusion: Patients from 18 years to 60 years HIV + treated(handled): * Patients presenting...
Eligibility Criteria
Inclusion
- Patients from 18 years to 60 years HIV + treated(handled):
- Patients presenting an undetectable viral load(responsibility) for at least 6 months and no more than year, by the use of a tritherapy containing 2 NUC + 1 IP.
- Patients presenting an immunosuppression "average" with a rate of T CD4 understood between 350 and 500 cells(units) by ml.
- Patients known for a perfect observance.
Exclusion
- Preliminary Use of an inhibitor of the integrase
- Patients presenting an opportunist infection and\\or an evolutionary cancer
- Patients benefiting from a treatment by IL-2, interferon-alpha, steroids or the other medicines known to modify the immunity.
- Pregnant Women
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01249560
Start Date
January 1 2011
End Date
March 1 2011
Last Update
November 30 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dellamonica
Nice, Alpes Maritimes, France, 06200